pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Lucentis
drug
save

ranibizumab

Marketedupdated 6mo ago
by Genentech Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval18 co-mentions · 9 sources
  • drugBYOOVIZ16 co-mentions · 8 sources
  • drugranibizumab SR14 co-mentions · 14 sources
  • drugranibizumab biosimilar13 co-mentions · 13 sources
  • companySamsung Bioepis Co Ltd8 co-mentions · 8 sources
  • companyXbrane Biopharma AB5 co-mentions · 5 sources
  • tagOphthalmology5 co-mentions · 5 sources
  • tagBiosimilar5 co-mentions · 5 sources

indications

investigational
Diabetic Macular Edema

all catalysts(0)

nothing on the calendar yet

Trials studying ranibizumab

  • phase3A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEactive not recruitingn=1,054
  • phase3Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)recruitingn=561
  • phase3A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DMEactive not recruitingn=672
  • phase4A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)recruitingn=188
  • phase3A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEactive not recruitingn=984
  • —A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Productsactive not recruitingn=6,000
  • phase3A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)active not recruitingn=68
  • phase3Extension Study for the Port Delivery System With Ranibizumab (Portal)recruitingn=1,000

News(10)

  • J&J bets $2.2B on Ollin’s vision loss drug
    The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.
    biopharma_dive · 19h ago
  • J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
    Johnson & Johnson has struck a deal to buy Ollin Biosciences for $2.2 billion upfront, establishing itself as a threat to Roche’s blockbuster eye disease drug Vabysmo.
    fiercebiotech · 1d ago
  • Recon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetes
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 19d ago
  • Merck reports mixed data for Lucentis competitor in diabetic macular edema
    Merck’s ophthalmology candidate met the primary endpoint in a pivotal study, but the full results raise questions about the drug’s commercial prospects. Merck said last month that remigromig was no…
    endpoints · 1mo ago
  • Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
    Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.
    biopharma_dive · 1mo ago
  • Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potential
    Merck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led analysts to predict “limited competitive potential” in diabetic macular ede…
    fiercebiotech · 1mo ago
  • Kodiak skyrockets on positive study data for 2 eye drugs
    The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
    biopharma_dive · 1mo ago
  • Merck reveals study success, and possible safety worries, for eye drug hopeful
    A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate among analysts.
    biopharma_dive · 1mo ago
  • Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
    Analysts were keen to see a new modality compete with Roche’s approved drug Lucentis in the late-stage trial but new safety issues could complicate the future for Merck’s candidate.
    biospace · 1mo ago
  • Merck sees pivotal victory for $3B eye disease prospect
    Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…
    fiercebiotech · 1mo ago
view all news mentions →
brand
Lucentis
generic
ranibizumab
indication
Choroidal Neovascularization
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?